Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 SAN DIEGO, Jan. 8, 2026 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
